Streck launches Liquid Biopsy Accelerator Grant to advance non-invasive cancer detection research
9 Jul 2025Industry news
Streck is thrilled to announce the launch of its inaugural Liquid Biopsy Accelerator Grant. This initiative aims to support innovative research in blood-based early cancer detection and other non-invasive diagnostic strategies.
The grant will award five applicants with $2,500 in product credit for use with Streck stabilization products. One grand prize winner will receive an additional $7,500 product credit and a sponsored trip to the American Association for Cancer Research (AACR) Annual Meeting in 2026.
“The future of diagnostics depends on researchers who can turn emerging technologies into practical solutions that improve lives,” said Kevin Billings, director of Business Segment – Stabilization at Streck. “Through this grant, we hope to accelerate promising liquid biopsy work and provide scientists with the resources they need to make meaningful progress.”
The grant is open to academic laboratories and early-stage companies based in the United States with research focused on translational or clinical applications of liquid biopsy. Applicants must use Streck stabilization products as part of their proposed work and will be evaluated based on scientific merit, innovation and alignment with the grant mission.
Proposals are due by August 31, 2025, at 11:59 p.m. CST. Selected applicants will be notified no later than November 12, 2025.
For full eligibility requirements and to apply, click here.
Related products
Request Quote for All Products
Protein Plus BCT™
StreckProtein Plus BCT is a direct draw whole blood collection tube intended for the stabilization of draw-time concentrations of plasma proteins for up to 5 days* at ambient temperature. *Depending on protein
Nucleic Acid BCT™
StreckNucleic Acid BCT is a direct draw venous whole blood collection device that maintains draw-time concentrations of cell-free DNA, cell-free RNA and extracellular vesicles for up to 7 days when stored at room temperature.? Once isolated from stored plasma, cell-free DNA and cell-free RNA are suitable for many downstream applications. Nucleic Acid BCT is currently available in a 5 mL volume. 10 mL volume is coming soon.
Cell-Free DNA BCT®
StreckFor In Vitro Diagnostic Use. Cell-Free DNA BCT is a direct-draw venous whole blood collection device intended for the collection, stabilization and transport of venous whole blood samples for use in conjunction with cell-free DNA next generation sequencing assays For that have been cleared or approved for use with samples collected into the Cell-Free DNA BCT device. Performance characteristics of this device have only been established on the Guardant360 CDx assay.